V

Vapotherm Inc
F:VA21

Watchlist Manager
Vapotherm Inc
F:VA21
Watchlist
Price: 2.976 EUR
Market Cap: €137.6m

Vapotherm Inc
Long-Term Debt

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Vapotherm Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
V
Vapotherm Inc
F:VA21
Long-Term Debt
$107.1m
CAGR 3-Years
34%
CAGR 5-Years
28%
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Long-Term Debt
$11.1B
CAGR 3-Years
8%
CAGR 5-Years
4%
CAGR 10-Years
7%
Stryker Corp
NYSE:SYK
Long-Term Debt
$14.9B
CAGR 3-Years
8%
CAGR 5-Years
2%
CAGR 10-Years
16%
Abbott Laboratories
NYSE:ABT
Long-Term Debt
$11.6B
CAGR 3-Years
-7%
CAGR 5-Years
-9%
CAGR 10-Years
7%
IDEXX Laboratories Inc
NASDAQ:IDXX
Long-Term Debt
$374.8m
CAGR 3-Years
-19%
CAGR 5-Years
-15%
CAGR 10-Years
-3%
Intuitive Surgical Inc
NASDAQ:ISRG
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Vapotherm Inc
Glance View

Market Cap
137.6m EUR
Industry
Health Care

Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.

VA21 Intrinsic Value
Not Available
V

See Also

What is Vapotherm Inc's Long-Term Debt?
Long-Term Debt
107.1m USD

Based on the financial report for Dec 31, 2023, Vapotherm Inc's Long-Term Debt amounts to 107.1m USD.

What is Vapotherm Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
28%

Over the last year, the Long-Term Debt growth was 10%. The average annual Long-Term Debt growth rates for Vapotherm Inc have been 34% over the past three years , 28% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett